Supernus Pharmaceuticals Ownership | Who Owns Supernus Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Supernus Pharmaceuticals Ownership Summary


Supernus Pharmaceuticals is owned by 101.24% institutional investors, 4.46% insiders. Blackrock is the largest institutional shareholder, holding 18.90% of SUPN shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 6.02% of its assets in Supernus Pharmaceuticals shares.

SUPN Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockSupernus Pharmaceuticals101.24%4.46%-5.70%
SectorHealthcare Stocks 35.74%11.83%52.43%
IndustrySpecialty & Generic Drug Manufacturers Stocks20.55%13.96%65.49%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock10.39M18.90%$278.00M
Blackrock funding, inc. /de8.80M15.58%$454.73M
Vanguard group6.05M10.72%$300.61M
Millennium management3.32M5.87%$171.40M
Dimensional fund advisors lp2.31M4.09%$119.24M
State street2.29M4.05%$118.27M
Macquarie management2.04M3.61%$105.30M
Armistice capital1.90M3.36%$97.97M
Renaissance1.71M3.02%$88.14M
Geode capital management1.62M2.88%$83.93M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Krensavage asset management280.68K5.67%$14.51M
Ashford capital management645.38K4.12%$33.36M
Sofinnova investments954.31K1.87%$49.33M
Villanova investment management34.93K1.85%$1.81M
Armistice capital1.90M1.74%$97.97M
Bruce100.00K1.48%$5.17M
Rice hall james & associates477.42K1.37%$24.68M
Third avenue management152.72K1.28%$7.89M
S&t bank/pa52.48K1.01%$2.71M
Stephens investment management group1.35M0.96%$69.85M

Top Buyers

HolderShares% AssetsChange
Citadel advisors1.49M0.01%1.04M
Millennium management3.32M0.07%675.91K
Assenagon asset management530.62K0.04%530.62K
Woodline partners lp449.00K0.09%449.00K
Freestone grove partners lp641.32K0.23%445.00K

Top Sellers

HolderShares% AssetsChange
Macquarie group---2.53M
Polar capital---1.00M
Point72 asset management1.32M0.09%-946.25K
Armistice capital1.90M1.74%-868.65K
Rubric capital management lp---595.37K

New Positions

HolderShares% AssetsChangeValue
Assenagon asset management530.62K0.04%530.62K$27.43M
Vanguard fiduciary trust369.25K0.00%369.25K$19.09M
Norges bank120.40K0.00%120.40K$5.98M
Hudson bay capital management lp90.82K0.02%90.82K$4.69M
Natixis85.20K0.02%85.20K$4.40M

Sold Out

HolderChange
Claris advisors, llc / mo /-1.00
Global financial private client-3.00
Flagship harbor advisors-5.00
Mendota financial group-5.00
Stephens consulting-10.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2026324-4.71%57,151,5250.06%1010.99%157-11.30%112-
Dec 31, 2025199-36.01%31,720,915-45.01%560.53%101-32.67%55-52.99%
Sep 30, 2025175-38.60%28,258,627-50.30%500.49%77-51.88%65-18.75%
Jun 30, 2025290-59,380,9950.51%1050.95%16311.64%80-15.79%
Mar 31, 2025286-2.72%59,007,517-0.81%1050.91%144-1.37%93-2.11%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
iShares Core S&P Small-Cap ETF3.49M6.02%774.00
Delaware Small Cap Core I2.00M3.62%-12.37K
Macquarie Small Cap Core I1.94M3.46%-145.53K
Vanguard US Total Market Shares ETF1.68M3.00%1.91K
Vanguard Total Stock Mkt Idx Inv1.74M3.00%6.44K
Nomura Small Cap Core I1.48M2.56%-46.97K
Nomura US Small Cap Core Equity1.48M2.56%1.48M
iShares Russell 2000 ETF1.30M2.23%10.90K
Vanguard Small Cap Index1.26M2.17%-2.42K
Polar Capital Biotech S Inc1.00M1.79%-175.00K

Recent Insider Transactions


DateNameRoleActivityValue
Mar 17, 2026Bhatt Padmanabh P. Sr. VP of IP, CSOSell$1.13M
Mar 17, 2026Bhatt Padmanabh P. Sr. VP of IP, CSOSell$1.38M
Mar 16, 2026Bhatt Padmanabh P. Sr. VP of IP, CSOSell$1.71M
Mar 18, 2026Bhatt Padmanabh P. Sr. VP of IP, CSOSell$338.82K
Mar 16, 2026Bhatt Padmanabh P. Sr. VP of IP, CSOSell$802.08K

Insider Transactions Trends


DateBuySell
2026 Q1-17
2025 Q4-9
2025 Q3-21
2025 Q2--
2025 Q1-3

SUPN Ownership FAQ


Who Owns Supernus Pharmaceuticals?

Supernus Pharmaceuticals shareholders are primarily institutional investors at 101.24%, followed by 4.46% insiders and -5.70% retail investors. The average institutional ownership in Supernus Pharmaceuticals's industry, Specialty & Generic Drug Manufacturers Stocks, is 20.55%, which Supernus Pharmaceuticals exceeds.

Who owns the most shares of Supernus Pharmaceuticals?

Supernus Pharmaceuticals’s largest shareholders are Blackrock (10.39M shares, 18.90%), Blackrock funding, inc. /de (8.8M shares, 15.58%), and Vanguard group (6.05M shares, 10.72%). Together, they hold 45.21% of Supernus Pharmaceuticals’s total shares outstanding.

Does Blackrock own Supernus Pharmaceuticals?

Yes, BlackRock owns 18.90% of Supernus Pharmaceuticals, totaling 10.39M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 278M$. In the last quarter, BlackRock increased its holdings by 30.28K shares, a 0.29% change.

Who is Supernus Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Krensavage asset management is Supernus Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 5.67% of its assets in 280.68K Supernus Pharmaceuticals shares, valued at 14.51M$.

Who is the top mutual fund holder of Supernus Pharmaceuticals shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of Supernus Pharmaceuticals shares, with 6.02% of its total shares outstanding invested in 3.49M Supernus Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools